Primary information |
---|
sequence ID | Seq_7752 |
Peptide sequence | SSYSKQFTSSTSYNRGDSTFE |
CancerPDF_ID | CancerPDF_ID17, CancerPDF_ID1034, |
PMID | 16896061,16395409 |
Protein Name | Fibrinogen alpha chain,Fibrinogen alpha chain |
UniprotKB Entry Name | FIBA_HUMAN,FIBA_HUMAN |
Fluid | Serum,Serum |
M/Z | 2379.03,2379.03 |
Charge | 1,1 |
Mass (in Da) | 2379.03,NA |
fdr | NA,NA |
Profiling Technique | MALDI-TOF,MALDI-TOF |
Peptide Identification technique | Q/TOF MS/MS,Q/TOF/TOF and LC-MS/MS |
Quantification Technique | NA,NA |
Labelled/Label Free | Label Free,Label Free |
FDR | NA,less than 1 “5 |
CancerPDF_ID | CancerPDF_ID17, CancerPDF_ID1034, |
p-Value | 1.00E-05,1.54E-16 |
Software | MASCOT,MASCOT (v 2.0.04 for Windows) |
Length | 21,21 |
Cancer Type | Metastatic thyroid carcinomas,"Advanced Prostate, Breast and Bladder cancer" |
Database | NCBI refseq Protein Database,NCBI refseq Protein Database |
Modification | NA,NA |
Number of Patients | 40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy" |
Regulation | NA,"For bladder (Lower) and for breast (Higher) Differential ion intensity in cancer compare to normal with Ratio of median intensity (patients/Controls) = 1.57, 0.22 and 1.71 in prostate, bladder and breast cancer respectively" |
Validation | Independent validation,Independent validation |
Sensitivity | 95% on independent dataset,97.5% on independent validation dataset |
Specificity | 95% on independent dataset,NA |
Accuracy | NA,97.5 % on validation dataset |
Peptide Atlas | NA |
IEDB | |